Prot# BUS230: Phase II Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Metastatic Pancreatic Cancer (CINJ# 070501-5324)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/1/06 → 3/31/10

Funding

  • Novartis Pharmaceuticals Corporation (CSTI571BUS230)